Grab Galaxy A36 5G with up to $150 instant trade-in credit and other offers
Samsung has launched its mid-range smartphone Galaxy A36 5G, earlier this month. The primary highlight of the smartphone is ...
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer
Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.
SussexWorld17h
New book for casual walkers in Sussex reveals easy short walks in South Downs
If hiking is not for you but you do fancy a nice walk in the Sussex countrsyide, the South Downs edition of Short Walks Made ...
Nearly 24,000 IPs behind wave of Palo Alto Global Protect scans
A significant spike in scanning activity targeting Palo Alto Network GlobalProtect login portals has been observed, with ...
Physician's Weekly19h
Distinct Clinical and Treatment Profiles of KRAS G12D and G12C in NSCLC
World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March ...
Trust running major Yorkshire hospitals among worst places to work in England
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
The Manila Times21h
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, ...